Zobrazeno 1 - 10
of 239
pro vyhledávání: '"Edward P Acosta"'
Autor:
Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta, Mark Bush, Helena Rabie, Patricia Flynn, Tim R. Cressey, Edward P. Acosta, Kristina M. Brooks, for the IMPAACT 2019 Study Team
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 8, Pp 1877-1891 (2024)
Abstract Introduction Once-daily fixed-dose combinations (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and children with HIV weighing ≥ 6 kg. This analysis assessed the ability of
Externí odkaz:
https://doaj.org/article/e73069ec1f6d483aaaca734cc3350bf7
Autor:
Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90485 (2014)
The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina
Externí odkaz:
https://doaj.org/article/bb218b722bfe4aa0a28c5e7a7e8619e1
Autor:
Daniel H Johnson, Deborah Sutherland, Edward P Acosta, Husamettin Erdem, Danielle Richardson, David W Haas
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82672 (2013)
Antiretroviral drugs vary in their central nervous system penetration, with better penetration possibly conferring neurocognitive benefit during human immunodeficiency virus (HIV) therapy. The efflux transporter gene ABCB1 is expressed in the blood-b
Externí odkaz:
https://doaj.org/article/4f19b6781a8e43cd972889e5d0889a04
Autor:
Iart Luca Shytaj, Sandro Norelli, Barbara Chirullo, Alessandro Della Corte, Matt Collins, Jake Yalley-Ogunro, Jack Greenhouse, Nunzio Iraci, Edward P Acosta, Maria Letizia Barreca, Mark G Lewis, Andrea Savarino
Publikováno v:
PLoS Pathogens, Vol 8, Iss 6, p e1002774 (2012)
Stably suppressed viremia during ART is essential for establishing reliable simian models for HIV/AIDS. We tested the efficacy of a multidrug ART (highly intensified ART) in a wide range of viremic conditions (10³-10⁷) viral RNA copies/mL) in SIVm
Externí odkaz:
https://doaj.org/article/0be750d7a056476b967074d1f16fbf0f
Autor:
Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of tri
Externí odkaz:
https://doaj.org/article/73538d58c45c449bae948e795b13f120
Autor:
Jennifer S, Guimbellot, Kevin J, Ryan, Justin D, Anderson, Kennedy L, Parker, Lauren, Victoria Odom, Steven M, Rowe, Edward P, Acosta
Publikováno v:
Pediatric Pulmonology. 57:2745-2753
Access to cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been gradually increasing for people with cystic fibrosis, the first of which was ivacaftor, a CFTR potentiator that is part of all clinically available modulator tre
Autor:
Behzad Etemad, Xiaoming Sun, Yijia Li, Meghan Melberg, Daniela Moisi, Rachel Gottlieb, Hayat Ahmed, Evgenia Aga, Ronald J. Bosch, Edward P. Acosta, Yuko Yuki, Maureen P. Martin, Mary Carrington, Rajesh T. Gandhi, Jeffrey M. Jacobson, Paul Volberding, Elizabeth Connick, Ronald Mitsuyasu, Ian Frank, Michael Saag, Joseph J. Eron, Daniel Skiest, David M. Margolis, Diane Havlir, Robert T. Schooley, Michael M. Lederman, Xu G. Yu, Jonathan Z. Li
Publikováno v:
Proceedings of the National Academy of Sciences. 120
HIV post-treatment controllers (PTCs) are rare individuals who maintain low levels of viremia after stopping antiretroviral therapy (ART). Understanding the mechanisms of HIV post-treatment control will inform development of strategies aiming at achi
Autor:
Christos Vaklavas, Erica M. Stringer-Reasor, Ahmed M. Elkhanany, Kevin J. Ryan, Yufeng Li, Charles P. Theuer, Edward P. Acosta, Shi Wei, Eddy S. Yang, William E. Grizzle, Andres Forero-Torres
Purpose In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative letroz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9169376e4e948e0e516012c68720fa61
https://doi.org/10.21203/rs.3.rs-2173087/v1
https://doi.org/10.21203/rs.3.rs-2173087/v1
Autor:
Edward P. Acosta, Megan Smith, Hector H. Gutierrez, Luz Helena Gutierrez Sanchez, Kevin J. Ryan, Jennifer S. Guimbellot, Janaina Nogueira Anderson, Kim W. Benner
Publikováno v:
J Cyst Fibros
The CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) is a genetic mutation-targeted treatment in cystic fibrosis that results in profound improvements in clinical outcomes. Each of the compounds are substrates of CYP3A4/5, the cytoch
Autor:
Kevin J. Ryan, Jennifer S. Guimbellot, Alexander E. Dowell, Kedria D. Reed-Walker, Corenna D. Kerstner-Wood, Justin D. Anderson, Zhongyu Liu, Edward P. Acosta
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1213
The triple combination modulator therapy (ETI, elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA)) is a recent advancement for the care of patients with cystic fibrosis. To aid in the development of clinical pharmacokinetics studies of this tre